Company / Cash & Equivalents
Monte Rosa Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$224.3M
FY2024
5-year range
$41.7M / $346.1M
FY2020-FY2024
Trend
+75.1%
vs FY2023
Sector context
#77 of 207
Health Care
What the data says
At $224M, Monte Rosa Therapeutics, Inc.'s cash & equivalents ranks #77 of 207 in the Health Care sector. Improved from $55M to $224M over the past 2 years.
Based on SEC 10-K filings.
$224M in FY2024 with a 3-year CAGR of -13.5%.
Improved from $55M to $224M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -13.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#77 of 207 in Health CareTop 37% of 207This company $224.3M Sector average $669.5M
▼
-66.5% below sector average
Key checks
Key Insights
- 3-year CAGR of -13.5%, indicating a declining trend.
- In FY2024, cash & equivalents increased 75.1% year-over-year.
- Ranks #77 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $224.3M | +75.1% |
| FY2023 | $128.1M | +133.3% |
| FY2022 | $54.9M | -84.1% |
| FY2021 | $346.1M | +729.9% |
| FY2020 | $41.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026